The Neddylation is an essential post-translational modification checkpoint for effector CD8+ T cells 4213

Abstract Description Optimal activation of CD8+ T cells is crucial for immunity-mediated destruction of cancer, requiring a substantial amount of proteins. Despite extensive studies emphasizing the role of transcriptional regulation in this process, the RNA profile is poorly correlated with protein levels. This discrepancy underscores the importance of post-translational modifications (PTMs) in controlling protein abundance during activation. We identify that neddylation, a recently discovered PTM, is activated upon TCR stimulation. Mechanistically, we found the rate-limiting enzyme of neddylation, NAE1, is induced by the NFATc1, a critical transcription factor downstream of TCR signaling. Our observation revealed that ablation of NAE1 significantly disturbed the proteomic landscape related to activation and mitochondrial function with minimal impact on the transcriptome. As a result, CD8+ T cells lacking NAE1 exhibited severely compromised activation, proliferation, and survival, which was accompanied by impaired mitochondrial function. Consistently, deletion of NAE1 in CD8+ T cells abolished their anti-tumor function and promoted tumor progression. By contrast, the overexpression of NAE1 improved the function of tumor-infiltrating CD8+ T cells. Overall, we uncovered neddylation, a previously underappreciated PTM, as a proteomic checkpoint for CD8+ T cell activation. Enforced expression of NAE1 offers promising therapeutic potential for boosting the anti-tumor CD8+ T cell responses. Funding Sources This work was supported by 1R01CA269984 (GX) from the National Institute of Health, CCR231013713 from Susan G. Komen (G.X.) and RSG-23-1036499-01 (G.X.) from the American Cancer Society. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

Authors

Publication Details

Journal
The Journal of Immunology
Published
2025-11-01
DOI
https://doi.org/10.1093/jimmun/vkaf283.1922
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Neddylation is an essential post-translational modification checkpoint for effector CD8+ T cells 4213

Zihai Li, Nuo Sun, Jiacheng Jin, Haitao Wen et al.
The Journal of Immunology
RNA modifications and cancer
article

The Neddylation is an essential post-translational modification checkpoint for effector CD8+ T cells 4213

Zihai Li, Nuo Sun, Jiacheng Jin, Haitao Wen, Gang Xin, Jianying Li, Fengxia Gao, Yi Wang
article en

Abstract

Abstract Description Optimal activation of CD8+ T cells is crucial for immunity-mediated destruction of cancer, requiring a substantial amount of proteins. Despite extensive studies emphasizing the role of transcriptional regulation in this process, the RNA profile is poorly correlated with protein levels. This discrepancy underscores the importance of post-translational modifications (PTMs) in controlling protein abundance during activation. We identify that neddylation, a recently discovered PTM, is activated upon TCR stimulation. Mechanistically, we found the rate-limiting enzyme of neddylation, NAE1, is induced by the NFATc1, a critical transcription factor downstream of TCR signaling. Our observation revealed that ablation of NAE1 significantly disturbed the proteomic landscape related to activation and mitochondrial function with minimal impact on the transcriptome. As a result, CD8+ T cells lacking NAE1 exhibited severely compromised activation, proliferation, and survival, which was accompanied by impaired mitochondrial function. Consistently, deletion of NAE1 in CD8+ T cells abolished their anti-tumor function and promoted tumor progression. By contrast, the overexpression of NAE1 improved the function of tumor-infiltrating CD8+ T cells. Overall, we uncovered neddylation, a previously underappreciated PTM, as a proteomic checkpoint for CD8+ T cell activation. Enforced expression of NAE1 offers promising therapeutic potential for boosting the anti-tumor CD8+ T cell responses. Funding Sources This work was supported by 1R01CA269984 (GX) from the National Institute of Health, CCR231013713 from Susan G. Komen (G.X.) and RSG-23-1036499-01 (G.X.) from the American Cancer Society. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

The Journal of ImmunologyVol. 214(Supplement_1)
Openalex Percentile: Top 68%
RNA modifications and cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.